Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001640455-18-000043)

Filing Details

Accession Number:: 0001640455-18-000043
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-03-19 18:42:03
Reporting Period:: 2018-03-15

Accepted Time:: 2018-03-19 18:42:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1640455	Jounce Therapeutics Inc.	JNCE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1353128	Gayle Barbara Duncan	C/O Jounce Therapeutics, Inc. 780 Memorial Drive Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-03-15	2,000	$4.21	2,000	No	4	M	Direct
Common Stock	Disposition	2018-03-15	2,000	$28.11	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2018-03-15	2,000	$0.00	2,000	$4.21

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
44,271		2026-05-09	No	4	M	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions.
The option shares vest and become exercisable in 16 quarterly installments from May 10, 2016.